Impel NeuroPharma announced that H. Stewart Parker, a prominent leader in Seattle's Biotechnology community, has joined Impel's Board of Directors. Most recently, Parker was the CEO of the Infection Disease Research Institute.
IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |